Clinical Trial Update: Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of sacubitril/valsartan (LCZ696) 200 mg added to amlodipine 5 mg versus amlodipine 5 mg alone in essential hype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Amlodipine (amlodipine)
• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-08-18